• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review.

作者信息

Vender Ronald, Turchin Irina, Lansang Perla, Prajapati Vimal H, Legault Mark, Barakat Maxime, Yeung Jensen

机构信息

Department of Medicine, Division of Dermatology, McMaster University, Hamilton, Ontario, Canada.

Dermatrials Research Inc, Hamilton, Ontario, Canada.

出版信息

JAAD Int. 2022 Jun 13;8:60-63. doi: 10.1016/j.jdin.2022.05.001. eCollection 2022 Sep.

DOI:10.1016/j.jdin.2022.05.001
PMID:35721301
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9204718/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/448a/9204718/6b1fb9448fdd/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/448a/9204718/6b1fb9448fdd/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/448a/9204718/6b1fb9448fdd/gr1.jpg

相似文献

1
Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review.
JAAD Int. 2022 Jun 13;8:60-63. doi: 10.1016/j.jdin.2022.05.001. eCollection 2022 Sep.
2
Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% Cream.0.01% 卤米松/0.045% 他扎罗汀固定复方洗剂治疗中度至重度斑块状银屑病的安全性和有效性：与0.05% 丙酸卤倍他索乳膏的比较
J Clin Aesthet Dermatol. 2018 Nov;11(11):15-19. Epub 2018 Nov 1.
3
Fixed Combination Halobetasol Propionate and Tazarotene Lotion for Plaque Psoriasis.卤米松/他扎罗汀复方制剂洗剂治疗斑块状银屑病。
Skin Therapy Lett. 2021 Nov;26(6):1-3.
4
Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis.加拿大关于使用丙酸氯倍他索/他扎罗汀洗剂治疗斑块状银屑病的专家共识。
Dermatol Ther (Heidelb). 2024 Jul;14(7):1917-1928. doi: 10.1007/s13555-024-01204-1. Epub 2024 Jun 25.
5
Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults.丙酸氯倍他索与0.01%/0.045%他扎罗汀洗剂对成人斑块状银屑病的治疗效果
Clin Cosmet Investig Dermatol. 2020 Jun 11;13:391-398. doi: 10.2147/CCID.S252426. eCollection 2020.
6
Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits.丙酸氯倍他索与他扎罗汀固定组合治疗银屑病：作用机制与治疗益处的叙述性综述
Dermatol Ther (Heidelb). 2021 Aug;11(4):1157-1174. doi: 10.1007/s13555-021-00560-6. Epub 2021 Jun 9.
7
Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis.卤倍他索和他扎罗汀：进一步明确一种独特的固定复方外用洗剂在中重度斑块状银屑病中的作用
J Drugs Dermatol. 2018 Dec 1;17(12):1290-1296.
8
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.一项评估卤米松/他扎罗汀固定组合治疗斑块状银屑病安全性和有效性的2期、多中心、双盲、随机、赋形剂对照临床研究。
J Drugs Dermatol. 2017 Mar 1;16(3):197-204.
9
Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.0.01% 卤倍他索/0.045% 他扎罗汀固定组合治疗重度局限性斑块状银屑病的疗效、安全性及耐受性：两项III期随机对照试验的事后分析
J Drugs Dermatol. 2019 Oct 1;18(10):1012-1018.
10
Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis.评估0.01%丙酸氯倍他索与0.045%他扎罗汀固定复方洗剂治疗中重度斑块状银屑病的协同效应。
J Drugs Dermatol. 2019 Mar 1;18(3):279-284..

本文引用的文献

1
Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort.难治性身体部位银屑病的流行病学：来自丹麦皮肤队列的数据。
BMC Dermatol. 2020 May 20;20(1):3. doi: 10.1186/s12895-020-00099-7.
2
Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.卤米松与他扎罗汀固定复方洗剂治疗中度至重度斑块状银屑病的安全性和有效性：两项3期研究的汇总分析
J Drugs Dermatol. 2018 Aug 1;17(8):855-861.
3
Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
固定剂量卤倍他索-他扎罗汀复方制剂治疗中重度斑块状银屑病的安全性和疗效：两项 3 期随机对照研究结果。
J Am Acad Dermatol. 2018 Aug;79(2):287-293. doi: 10.1016/j.jaad.2018.03.040. Epub 2018 Apr 1.
4
Moderate Psoriasis: A Proposed Definition.中度银屑病：一个拟议的定义。
Actas Dermosifiliogr. 2017 Dec;108(10):911-917. doi: 10.1016/j.ad.2017.07.002. Epub 2017 Aug 17.
5
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.一项评估卤米松/他扎罗汀固定组合治疗斑块状银屑病安全性和有效性的2期、多中心、双盲、随机、赋形剂对照临床研究。
J Drugs Dermatol. 2017 Mar 1;16(3):197-204.